Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 14/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PKLR | P30613 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207451 | 0.87 | FASN (0.51) | FASNALDH1A1KMT2APOLBMAPT | |
| SCHEMBL4203393 | 0.82 | KDM4E (0.55) | FASNALDH1A1 | |
| SCHEMBL4193612 | 0.82 | FASN (0.49) | FASN | |
| SCHEMBL4187265 | 0.81 | PKLR (0.52) | PKLR | |
| SCHEMBL4203520 | 0.81 | MEN1 (0.49) | FASNCYP3A4PKLRKMT2APOLB | |
| SCHEMBL4785060 | 0.80 | FASN (0.42) | FASNPKLRKMT2A | |
| SCHEMBL4198155 | 0.79 | FASN (0.65) | FASN | |
| SCHEMBL4191253 | 0.76 | FASN (0.63) | FASNKMT2APOLBMAPT | |
| SCHEMBL4202962 | 0.74 | FASN (0.61) | FASN | |
| SCHEMBL4197020 | 0.74 | FASN (0.59) | FASNCYP3A4USP2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | FASN 3/4885CYP3A4 3112/4885PKLR 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.